智通财经APP获悉，香港联交所最新资料显示，8月5日，山东墨龙(00568)股东将股票由港股通(沪)转入 中银国际证券，转仓市值6362.8万港元，占比5.96%。 本报告期，归属于上市公司股东的净利润同比减少，主要系上年同期出售两家子公司股权产生的投资收 益(为一次性的非经常性收益)影响所致。 据山东墨龙发布公告，该公司预计2025年上半年归属于上市公司股东的净利润1000万元-1300万元，同 比下降92.36%-94.12%。 ...

Group 1 - The core point of the article indicates that Shandong Molong (002490)(00568) has transferred shares worth HKD 112 million from Bank of China (Hong Kong) to the Hong Kong Stock Connect, representing 9.92% of the total shares [1] - Shandong Molong expects a net profit attributable to shareholders of the listed company to be between RMB 10 million and RMB 13 million for the first half of 2025, reflecting a year-on-year decline of 92.36% to 94.12% [1] - The decrease in net profit is primarily due to the impact of one-time non-recurring gains from the sale of two subsidiaries in the same period last year [1]

Core Viewpoint - The article discusses the transfer of shares of Innovent Biologics (09939) from Futu Securities International Hong Kong to BOC International Securities, with a total market value of HKD 124 million, representing 11.04% of the shares [1] Group 1: Share Transfer and Agreement - On July 31, shareholders of Innovent Biologics transferred shares valued at HKD 124 million to BOC International Securities, accounting for 11.04% of the total shares [1] - Innovent Biologics announced an agreement with Dr. Tong Youzhi and the seller (KT International Investment Limited) to sell 20.673 million shares at a price of HKD 2.08 per share, which is approximately 4.62% of the company's issued share capital [1] Group 2: Fundraising Purpose - The placement and subscription are aimed at supplementing the long-term funding for the group's general business and growth strategy [1] - The net proceeds from the subscription are estimated to be approximately HKD 40.34 million after deducting related expenses, which will be used for general working capital and business operations [1]

香港联交所最新资料显示，7月31日，神话世界(00582)股东将股票由中富证券转入大圣证券，转仓市值 2201.57万港元，占比8.61%。 神话世界公布，已于2025年7月15日完成配售约3.04亿股配售股份，每股配售股份0.118港元，净筹约 3540万港元。 ...

香港联交所最新资料显示，7月31日，开拓药业-B(09939)股东将股票由富途证券国际香港转入中银国际 证券，转仓市值1.24亿港元，占比11.04%。 进行配售事项及认购事项旨在补充集团的一般业务及增长策略的长期资金。董事认为，配售事项及认购 事项亦将为公司提供进一步集资的机会，同时扩大公司的股东基础及资本基础。经扣除相关费用及开支 后，认购事项的所得款项净额估计约为4034万港元。公司拟将认购事项所得款项净额用于集团的一般营 运资金及一般业务。 开拓药业发布公告，2025年8月1日(交易时段前)，公司、童友之博士及卖方(即KT International Investment Limited，由童博士全资拥有)与配售代理(即中银国际)订立该协议，据此，(i)卖方同意出售而 配售代理同意(作为卖方的代理)尽最大努力促使买方按每股股份2.08港元的价格购买卖方持有的合共 2067.3万股股份，相当于公司于本公告日期的已发行股本约4.62%；及(ii)卖方有条件同意作为委托人按 认购价(相当于配售价每股股份2.08港元)认购而公司有条件同意发行2067.3万股新股份(即认购股份)。 ...

Group 1 - The core point of the article highlights a significant shareholder transfer of ZTE Corporation's stock from HSBC to Citibank, valued at HKD 666 million, representing 3.42% of the company's shares [1] - ZTE Corporation's Q1 2025 financial report indicates a revenue of RMB 32.968 billion, reflecting a year-on-year increase of 7.82% [1] - The net profit attributable to ordinary shareholders decreased by 10.5% to RMB 2.453 billion, with basic earnings per share reported at RMB 0.51 [1]

Group 1 - The core point of the article highlights the transfer of shares of Changfei Fiber Optics (06869) from J.P. Morgan Broking (Hong Kong) Limited to Citibank, with a market value of HKD 963 million, accounting for 13.91% of the total shares [1] Group 2 - For the financial performance, Changfei Fiber Optics reported a total revenue of CNY 12.197 billion for 2024, representing a year-on-year decrease of 8.65% [1] - The net profit attributable to shareholders was CNY 676 million, showing a significant year-on-year decline of 47.91% [1] - The net cash flow from operating activities was CNY 1.783 billion, which reflects a year-on-year increase of 17.76% [1] - The basic earnings per share were CNY 0.89, and the weighted average return on equity was 5.83% [1]